Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab andor Ranibizumab for Neovascular Age-Related Macular Degeneration
Joint Authors
Griffin, David R.
Richmond, Preston P.
Olson, John C.
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-11-20
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Purpose.
To assess whether intravitreal aflibercept (2.0 mg) can effectively reduce persistent macular exudate and enhance visual acuity in ranibizumab (0.5 mg) and/or bevacizumab (1.25 mg) treatment resistant patients with neovascular age-related macular degeneration.
Methods.
This retrospective study included 47 treatment resistant eyes from 47 patients switched to intravitreal aflibercept injections after receiving a minimum of 3 injections with either ranibizumab or bevacizumab.
Snellen visual acuity and optical coherence tomography were assessed just prior to the first injection (baseline) and prior to the fourth injection (final).
Additionally, anatomical regions of persistent macular exudate were tracked to determine if these areas yielded varying responses to aflibercept.
Results.
At baseline, patients had received an average of 11.3 injections with any prior anti-VEGF drug (SD 5.96).
For whole group analysis, baseline and final central retinal thickness were 370.57 µm and 295.7 µm ( P ≤ .
001 ), respectively.
Baseline and final retinal fluid volumes were 4.81 mm3 and 4.37 mm3 ( P ≤ .
001 ), respectively.
Baseline and final logMAR were 0.56 and 0.53 ( P = 0.301 ), respectively.
Anatomic location of persistent exudate did not appreciably alter treatment outcome.
Conclusion.
Central retinal thickness and total retinal fluid volume were reduced in ranibizumab and/or bevacizumab treatment resistant patients following three aflibercept injections.
No appreciable change in visual acuity was noted.
American Psychological Association (APA)
Griffin, David R.& Richmond, Preston P.& Olson, John C.. 2014. Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab andor Ranibizumab for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology،Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1042542
Modern Language Association (MLA)
Griffin, David R.…[et al.]. Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab andor Ranibizumab for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology No. 2014 (2014), pp.1-6.
https://search.emarefa.net/detail/BIM-1042542
American Medical Association (AMA)
Griffin, David R.& Richmond, Preston P.& Olson, John C.. Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab andor Ranibizumab for Neovascular Age-Related Macular Degeneration. Journal of Ophthalmology. 2014. Vol. 2014, no. 2014, pp.1-6.
https://search.emarefa.net/detail/BIM-1042542
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1042542